Genmab and AbbVie Report Phase 3 EPCORE DLBCL‑1 Results – U.S. Overall Survival Endpoint Not Met
Clinical Trial Overview
Genmab A/S and its partner AbbVie Inc. announced the final clinical outcomes of the Phase 3 EPCORE DLBCL‑1 study, a randomized, open‑label investigation of the bispecific antibody epcoritamab in patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL). The study enrolled 1,100 participants across 12 countries, with a 2:1 randomization to epcoritamab plus standard of care (SOC) versus SOC alone. The primary efficacy endpoint in the United States was overall survival (OS), defined as the time from randomization to death from any cause, measured at 24 months. Secondary endpoints included progression‑free survival (PFS), objective response rate (ORR), duration of response, and safety profile.
Efficacy Outcomes
Overall Survival
24‑month OS: 48.2 % (epcoritamab + SOC) vs. 44.6 % (SOC).
Hazard ratio (HR) = 0.86 (95 % CI: 0.68–1.09); p = 0.21.
The result did not meet the prespecified superiority criterion (HR < 0.78) and was not statistically significant.
Progression‑Free Survival
24‑month PFS: 36.8 % vs. 28.5 %.
HR = 0.73 (95 % CI: 0.60–0.89); p < 0.001.
PFS met the prespecified superiority threshold.
Objective Response Rate
ORR: 65.4 % vs. 49.6 % (epcoritamab + SOC vs. SOC).
Statistical significance achieved (p < 0.001).
Duration of Response
Median: 12.4 months (epcoritamab + SOC) vs. 9.1 months (SOC).
Safety Profile
Adverse events (AEs) were consistent with the known safety profile of bispecific antibodies:
| AE Category | Incidence (epcoritamab + SOC) | Incidence (SOC) |
|---|---|---|
| Cytokine release syndrome (CRS) | 17.6 % (grade ≥ 3: 2.3 %) | N/A |
| Hematologic toxicity | 28.4 % (grade ≥ 3: 6.5 %) | 23.1 % (grade ≥ 3: 4.1 %) |
| Injection‑site reactions | 14.9 % | 9.7 % |
Serious infections occurred in 9.2 % of patients receiving epcoritamab versus 7.4 % in the SOC arm. No new safety signals emerged compared with earlier phase trials.
Regulatory Context
In the United States, the Food and Drug Administration (FDA) requires robust evidence of OS improvement for approval of therapies in relapsed/refractory DLBCL. The failure to meet the primary OS endpoint in EPCORE DLBCL‑1 thus represents a significant regulatory hurdle. Nonetheless, the European Medicines Agency (EMA) may consider the totality of evidence—including PFS, ORR, and safety—under its accelerated assessment framework. The company is exploring a composite primary endpoint strategy for potential resubmission, incorporating both OS and PFS to satisfy regulatory requirements.
Market Impact
Genmab’s shares dipped approximately 2.7 % on the day of the announcement, a modest decline relative to the broader Danish OMX Copenhagen index, which experienced a 0.5 % intraday swing. Analysts projected that the OS miss could depress Genmab’s valuation by 3–5 % in the short term, given the weight of the DLBCL program in the company’s revenue forecast. However, several market commentators highlighted that Genmab’s pipeline breadth—encompassing bispecific antibodies for multiple indications (e.g., BCMA‑targeting agents for multiple myeloma)—and its robust partnership network mitigate the immediate financial impact.
Implications for Patient Care
- Clinical Practice: The OS data suggest that while epcoritamab can improve disease control, its survival benefit remains uncertain. Clinicians may consider the therapy within the context of individual patient risk profiles and alternative salvage options.
- Health Systems: Payers and policymakers must weigh the cost‑effectiveness of epcoritamab given the lack of OS improvement, balancing the drug’s manufacturing cost against its demonstrated PFS benefit.
- Future Directions: Genmab is accelerating preclinical work on next‑generation bispecifics and exploring combination strategies with CAR‑T therapies to enhance OS outcomes.
Conclusion
The Phase 3 EPCORE DLBCL‑1 study confirms the efficacy of epcoritamab in improving PFS and ORR but falls short of the OS threshold required for U.S. approval. The company’s forthcoming regulatory strategy will likely involve a composite endpoint and further safety analyses to strengthen the benefit–risk profile. While the immediate market reaction reflects the clinical outcome, Genmab’s diversified pipeline and partnership ecosystem position it for sustained long‑term growth in the biopharmaceutical landscape.
